| 2025/02/27 | 18:05:16 | BOD of Medeon’s major subsidiary Medeologix Corporation resolved to convene the 2025 Annual Shareholders’ meeting | |
| SEQ_NO |
6 |
Date of announcement |
2025/02/27 |
Time of announcement |
18:05:16 |
| Subject |
BOD of Medeon’s major subsidiary Medeologix Corporation resolved to convene the 2025 Annual Shareholders’ meeting |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2025/02/27
2.General shareholders’ meeting date:2025/05/23
3.General shareholders’ meeting location:Online Teams Meeting.
4.Cause for convening the meeting I.Reported matters:
(1) 2024 Business Report
(2) 2024 Supervisor’s Review Report
5.Cause for convening the meeting II.Acknowledged matters:
(1) 2024 Business Report and Financial Statements
(2) 2024 deficit offset proposal
6.Cause for convening the meeting III, Matters for Discussion:NA
7.Cause for convening the meeting IV.Election matters:NA
8.Cause for convening the meeting V.Other Proposals:NA
9.Cause for convening the meeting VI.Extemporary Motions:NA
10.Book closure starting date:2025/04/24
11.Book closure ending date:2025/05/23
12.Any other matters that need to be specified:NA |
|
| 2025/02/27 | 18:00:13 | BOD of Medeon’s major subsidiary Medeologix Corporation resolved not to distribute dividends | |
| SEQ_NO |
5 |
Date of announcement |
2025/02/27 |
Time of announcement |
18:00:13 |
| Subject |
BOD of Medeon’s major subsidiary Medeologix Corporation resolved not to distribute dividends |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2025/02/27
2.Type and monetary amount of dividend distribution:not to distribute.
3.Any other matters that need to be specified:None. |
|
| 2025/02/27 | 17:51:53 | Medeon Board of Directors resolved the convening of the 2025 Annual Shareholders’ Meeting | |
| SEQ_NO |
4 |
Date of announcement |
2025/02/27 |
Time of announcement |
17:51:53 |
| Subject |
Medeon Board of Directors resolved the convening of the 2025 Annual Shareholders' Meeting |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2025/02/27
2.General shareholders’ meeting date:2025/06/20
3.General shareholders’ meeting location:
11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City, Taiwan (R.O.C.)
(MasterLink Securities Conference Room)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):
Physical shareholders meeting
5.Cause for convening the meeting I.Reported matters:
(1) To Report the Company’s 2024 Business Report
(2) To Report Audit Committee’s Review Report on the
2024 Financial Statements
(3) To Report the Implementation Status of the Private Placement
(4) To Report the Directors’ Remuneration for the year 2024
6.Cause for convening the meeting II.Acknowledged matters:
(1) To ratify the Company’s 2024 Business Report and Financial Statements
(2) To Ratify the Company’s 2024 deficit offset proposal
7.Cause for convening the meeting III.Matters for Discussion:
(1) Proposal of the private placement by issuing common shares.
(2) To approve the amendment to the Articles of Incorporation.
(3) To release directors or its representatives from Non-Competition
Restrictions
8.Cause for convening the meeting IV.Election matters:None.
9.Cause for convening the meeting V.Other Proposals:None.
10.Cause for convening the meeting VI.Extemporary Motions:None.
11.Book closure starting date:2025/04/22
12.Book closure ending date:2025/06/20
13.Any other matters that need to be specified:None. |
|
| 2025/02/27 | 17:35:40 | Medeon Board of Directors resolved the plan for dividend distribution | |
| SEQ_NO |
3 |
Date of announcement |
2025/02/27 |
Time of announcement |
17:35:40 |
| Subject |
Medeon Board of Directors resolved the plan for dividend distribution |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2025/02/27
2.Year or quarter which dividends belong to :2024
3.Period which dividends belong to:2024/01/01~2024/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10 |
|
| 2025/02/27 | 17:15:47 | Medeon Board of Directors resolved the proposal of private placement to issue additional common shares | |
| SEQ_NO |
2 |
Date of announcement |
2025/02/27 |
Time of announcement |
17:15:47 |
| Subject |
Medeon Board of Directors resolved the proposal of private placement to issue additional common shares |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2025/02/27
2.Types of securities privately placed:The Company’s common shares
3.Counterparties for private placement and their relationship
with the Company:
According to Article 43-6 of the Securities and Exchange Act, the
Financial Supervisory Commission’s Order No. SFB 11220383220 issued on
September 12, 2023, and the Directions for Public Companies Conducting
Private Placement of Securities, only the following parties are qualified
as specific investors of the private placement:
A.Insiders of the Company
The reason is that insiders know the operation of the Company very well
and can directly or indirectly contribute to the operation of the
Company. Therefore, placees in this instance of private placement
include the insiders. The list of these insiders is shown below:
a. The list of these insiders and the relation with the Company:
(1) Medeon, Inc. (USA)/ Institutional Director of the Company
(2) Center Laboratories, Inc./ Institutional Director of the Company
(3) Yue Teh Jang/ Representative of Medeon, Inc. of the USA, an
Institutional Director of the Company. Chairman and President of
the Company
(4) Jung-Chin Lin/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(5) Chih-Hsiung Wu/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(6) Chi-Hang Yang/ Independent Director of the Company
(7) Chia-Ying Ma/ Independent Director of the Company
(8) Jien-Wei Yeh/ Independent Director of the Company
(9) Feng Shyang Yang/ Independent Director of the Company
(10) Albert Weng/ Manager of the Company
(11) Greta Chang/ Manager of the Company
(12) Jenny Chen/ Manager of the Company
(13) Pei Chen/ Manager of the Company
(14) Tori Lin/ Accounting Officer of the Company
b. Institutional investors’ Names of the top 10 shareholders and
proportion of shareholding and the relation with the Company:
(1) Medeon, Inc. (USA)
Yue Teh Jang (100%)/ The Chairman of this company is the Chairman
and President of the Company.
(2) Center Laboratories, Inc.
Li Rong Technology Co., Ltd. (9.13%)/ The Chairman of this company
is the spouse of the representative of an Institutional Director
of the Company.
Royal Food Co., Ltd. (5.72%)/ The Chairman of this company is a
representative of an Institutional Director of the Company.
Jason Technology Co., Ltd. (3.51%)/ The Chairman of this company
is the spouse of the representative of an Institutional Director
of the Company.
Yuanta Securities Co., Ltd. in Custody for Mining Investment Fund
of GL Capital Group (2.71%)/ None
Farglory Life Insurance Inc. (1.48%)/ None
You De Investment Consulting Co., Ltd. (1.14%)/ The Chairman of
this company is also the Chairperson of an Institutional Director
of the Company.
JPMorgan Chase Bank N.A. Taipei Branch in Custody for Vanguard
Total International Stock Index Fund, a series of Vanguard Star
Funds (1.00%)/ None
Mumozi Inc. (0.94%)/ None
Yong Lian Co., Ltd. (0.91%)/ None
Vanguard Emerging Markets Stock Index Fund, a Series of Vanguard
International Equity Index Funds (0.91%)/ None
B.Placees should be strategic investors: It is necessary to bring in
strategic investors that could contribute to the development of the
Company in the future, improvement of financial structure, and upgrade
the profitability of the Company. It is expected that with the
assistance of their capital, technology and knowledge, the Company
will be able to grow steadily in the future.
The Company has not yet pinpointed specific investors for investment.
The Company request the Shareholders’ Meeting to authorize the Board with
full power of attorney to search for the placees.
4.Number of shares or bonds privately placed:
Within the limit of 35,000,000 shares
5.Amount limit of the private placement:
Within the limit of 35,000,000 shares of common stock, the private placement
will be conducted in installments within one year from the date of the
shareholders’ meeting, with the maximum number of installments not
exceeding three.
6.Pricing basis of private placement and its reasonableness:
The reference price for the private placement is set at the higher of the
following two benchmark prices:
A.The average of the closing prices of common shares for one or three or
five (alternative) business days prior to the pricing date, excluding the
ex-rights and dividends of the nil-paid allotment of shares and after
adding back the capital reduction and ex-rights.
B.The average of the closing prices of the common shares for the 30 business
days preceding the pricing date, excluding the ex-rights and dividends of
the nil-paid allotment, and after adding back the capital reduction and
ex-rights.
The price of common shares issued in the private placement shall be set at
a level not less than 80% of the reference price. The actual issuance price
of the private placement is proposed to the shareholders’ meeting to
authorize the board of directors to determine the price within a range not
lower than the percentage resolved at the shareholders’ meeting, taking
into account the prevailing market conditions on the pricing date.
7.Use of the funds raised in the private placement:
The purpose of each tranche is to increase working capital, accelerate
product development, invest in subsidiaries and the medical industry,
and develop the Group’s strategic objectives.
8.Reasons for conducting non-public offering:
Considering the timing, convenience and cost of issuance, private
placement of securities can be accomplished quickly and easily.
In addition, securities invested through private placement cannot be
transferred in a period of 3 years after issuing. This helps to assure
the long-term stable relation between the investors and the Company.
As such, offering securities through private placement is adopted.
9.Objections or qualified opinions from independent Board of Directors:None.
10.Actual price determination date:NA
11.Reference price:NA
12.Actual private placement price, and conversion or
subscription price:NA
13.Rights and obligations of these new shares privately placed:
In principle, the rights and obligations of the common shares in the
private placement are the same as those of the Company’s existing
common shares; however, in accordance with the Securities and Exchange
Act, the common shares in the private placement may not be sold within
three years from the date of delivery, except to the parties to whom
they are transferred in accordance with Article 43-8 of the Securities
and Exchange Act. After three years from the date of delivery, the
Company intends to request the shareholders’ meeting to authorize
the Board of Directors to apply to the relevant authorities for a
public offering and listing of the Company’s common shares in
accordance with the relevant regulations.
14.Reference date for any additional share exchange, stock
swap, or subscription:NA
15.Possible dilution of equity in case of any additional share
exchange, stock swap, or subscription:NA
16.For additional share exchange or subscription, possible
influence of change in shareholding ratio of TPEx -listed
common shares if all privately placed corporate bonds are
converted and shares subscribed for (no.of TPEx -listed
common shares (a), (a) / outstanding common shares):NA
17.Please explain any countermeasures for lower circulation
in shareholding if the aforesaid estimated no.of TPEx -listed
common shares does not reach 5 million and the ratio does not
reach 25%:NA
18.Any other matters that need to be specified:
(1)The main contents of the private placement plan, including the actual
issue price, the number of shares to be issued, the terms of the issue,
the pricing date, the base date of the capital increase, the planned
projects, the amount to be raised, the estimated progress, the estimated
benefits to be generated, and all other matters related to the issue plan,
in addition to the pricing percentage of the private placement. The above
and in the future, in the event of changes in laws and regulations,
amendments as directed by the competent authorities, or amendments based
on operational evaluations or in response to objective market conditions,
the shareholders’ meeting will also be requested to authorize the Board
of Directors to handle such matters at its sole discretion.
(2)In connection with the private placement of securities, it is proposed
that the shareholders’ meeting authorize the chairman of the board of
directors or his or her designee to sign and negotiate on behalf of the
Company all contracts and documents relating to the private placement
and to conduct all matters necessary for the Company in connection with
the private placement. |
|
| 2025/02/27 | 16:43:27 | Medeon Board of Directors approved the 2024Q3 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2025/02/27 |
Time of announcement |
16:43:27 |
| Subject |
Medeon Board of Directors approved the 2024Q3 consolidated financial reports |
| Date of events |
2025/02/27
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2025/02/27
2.Date of the audit committee approved:2025/02/27
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01~2024/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD): 292,808
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD): 83,414
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD): (885,613)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(858,643)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(870,523)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD): (805,512)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD): (8.74)
11.Total assets end of the period (thousand NTD): 1,877,743
12.Total liabilities end of the period
(thousand NTD): 341,840
13.Equity attributable to owners of parent end of the
period (thousand NTD): 1,520,192
14.Any other matters that need to be specified:None |
|
| 2025/02/19 | 16:55:34 | Announcement for the Board of Directors meeting date to approve the fourth-quarter 2024 financial report | |
| SEQ_NO |
1 |
Date of announcement |
2025/02/19 |
Time of announcement |
16:55:34 |
| Subject |
Announcement for the Board of Directors meeting date to approve the fourth-quarter 2024 financial report |
| Date of events |
2025/02/19
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2025/02/19
2.Expected date of the board of directors meeting is convened:2025/02/27
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors: Fourth-Quarter 2024
4.Any other matters that need to be specified:None |
|
| 2025/01/21 | 17:33:29 | Announcement in accordance with Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies | |
| SEQ_NO |
2 |
Date of announcement |
2025/01/21 |
Time of announcement |
17:33:29 |
| Subject |
Announcement in accordance with Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies |
| Date of events |
2025/01/21
|
To which item it meets |
paragraph 23 |
| Statement |
1.Date of occurrence of the event:2025/01/21
2.Funding recipient (1)Name(2)Relationship with lender
(3)Lending limit (thousand NTD)(4)Starting outstanding
balance (thousand NTD)(5)New loan (thousand NTD)(6)Is
it part of a scheduled allocation or revolving limit
for the same recipient that the chairman is authorized
by the board of directors to allocate(7)Outstanding
balance (thousand NTD) up to the date of occurrence
(8)Reason for new loan (thousand NTD):
(1)Name?GPMC
(2)Relationship with lender?GPMC is a subsidiary of Medeon Biodesign
which holds 89.27% of the shares.
(3)Lending limit (thousand NTD)?G171,983
(4)Starting outstanding balance (thousand NTD)?G0
(5)New loan (thousand NTD)?G165,000
(6)Is it part of a scheduled allocation or revolving limit for the same
recipient that the chairman is authorized by the board of directors to
allocate?GYes
(7)Outstanding balance (thousand NTD) up to the date of occurrence?G
165,000
(8)Reason for new loan (thousand NTD)?Gworking capital requirements
3.For collaterals provided by the loan recipient, the
(1)Content(2)Value (thousand NTD):
(1)Content?GNone
(2)Value (thousand NTD)?G0
4.For the latest financial reports of the loan recipient, the
(1)Capital (thousand NTD)(2)Cumulative gains/losses
(thousand NTD):
(1)Capital (thousand NTD)?G111,890
(2)Cumulative gains/losses (thousand NTD)?G-1,187,638
5.Method of calculation of interest:With an annual interest rate of 3%
6.For repayment, the(1)Condition(2)Date:
(1)Condition?GBased on the contract
(2)Date?GBased on the contract
7.The amount of monetary loans extended to others as
of the date of occurrence (thousand NTD):165,000
8.The total amount of monetary loans extended to others
as a percentage of the public company’s net worth on
the latest financial statements as of the date of
occurrence:9.59%
9.Sources of funds for the company to extend monetary
loans to others:Other
10.Any other matters that need to be specified:
The source of funds loaned by the Company to PMC is working capital. |
|
| 2025/01/21 | 17:15:40 | Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation | |
| SEQ_NO |
1 |
Date of announcement |
2025/01/21 |
Time of announcement |
17:15:40 |
| Subject |
Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation |
| Date of events |
2025/01/21
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
The new common shares issued for capital increase by
Medeologix Corporation
2.Date of occurrence of the event:2025/01/21~2025/01/21
3.Volume, unit price, and total monetary amount of the transaction:
Transaction Volume: No more than 8,960,000 common shares
Issued price per share: NTD 25
Total monetary amount: No more than NTD 224,000,000
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix Corporation, the subsidiary of Medeon Biodesign
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The subsidiary of Medeon Biodesign
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer: N/A
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Payment will be made according to the fund
raising schedule resolved by Medeologix’s board.
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Medeon Board of Director’s resolution dated 2025/1/21
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:NTD 8.92
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):
No more than 61,774,174 shares
Cumulative monetary amount (including the current transaction):
No more than NTD 1,379,000 thousand.
Cumulative shareholding percentage: No more than 97.09%
The status of any restriction of rights (e.g., pledges): None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 57.35%
Current ratio of securities investment to the equity attributable to
owners of the parent: 80.18%
Working capital: NTD 1,593,781 thousand.
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
Long-term Equity Investment
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:Yes
18.Date of the Board of Directors’ resolution:2025/01/21
19.Date of ratification by supervisors or approval by
the Audit Committee:2025/01/21
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:No
21.Name of the CPA firm:Horng Yow Certified Public Accountants
22.Name of the CPA:JUYU TANG
23.License no.of the CPA:
Financial-Supervisory-Securities-Corporate-0970013154
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
27.Source of funds:working capital
28.Any other matters that need to be specified:None |
|
| 2025/01/14 | 17:34:05 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix LLC. | |
| SEQ_NO |
3 |
Date of announcement |
2025/01/14 |
Time of announcement |
17:34:05 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the BOD approved the incremental investment to its subsidiary, Medeologix LLC. |
| Date of events |
2025/01/14
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):Medeologix LLC’s interest
2.Date of occurrence of the event:2024/02/01~2025/01/14
3.Volume, unit price, and total monetary amount of the transaction:
2024/2/1 total transaction amount: US$1,000,000
2024/11/15 total transaction amount: US$300,000
The total transaction amount: The Board of Directors of Medeologix
Corporation has set an investment cap for Medeologix LLC at no more
than US$3,000,000 within one year. The actual investment amount is
authorized to be determined by the Chairman of Medeologix Corporation
based on the operational needs of Medeologix LLC.
4.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix LLC, the 100%-owned subsidiary of Medeologix Corporation
5.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The 100%-owned subsidiary of Medeologix Corporation
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer: N/A
6.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
8.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
9.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Invest according to Medeologix LLC’s
capital needs
10.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
Resolutions of Medeologix Corporation ‘s Board of Directors dated
2024/1/17 and 2025/1/14.
11.Net worth per share of the Company’s underlying securities
acquired or disposed of:N/A
12.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):N/A
Cumulative monetary amount (including the current transaction):
No more than US$ 14,178,512
Cumulative shareholding percentage: 100% interest
The status of any restriction of rights (e.g., pledges): None
13.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 17.84%
Current ratio of securities investment to the equity attributable to
owners of the parent: 24.94%
Working capital: NTD 1,593,781 thousand.
14.Broker and broker’s fee:None
15.Concrete purpose or use of the acquisition or disposal:
Long-term Investment
16.Whether the directors expressed any objection to the current
transaction:None
17.Whether the counterparty of the current transaction
is a related party:Yes
18.Date of the Board of Directors’ resolution:2025/01/14
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:N/A
21.Name of the CPA firm:N/A
22.Name of the CPA:N/A
23.License no.of the CPA:N/A
24.Whether the transaction involved in change of business model:No
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
27.Source of funds:2025 Cash Capital Increase
28.Any other matters that need to be specified:
The Board of Directors of Medeologix Corporation held on 2024/1/17,
and 2025/1/14 ,resolved that the respective investment amounts within
one year in Medeologix LLC shall be no more than US$3,000,000 and
US$3,000,000. The Board authorizes the Chairman to decide the actual
investment amount according to the operating needs of Medeologix LLC. |
|
